Literature DB >> 20401463

Is there a human model for the 'metabolic syndrome' with a defined aetiology?

P Gorden, B C Lupsa, A Y Chong, A O Lungu.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20401463      PMCID： PMC3499968          DOI： 10.1007/s00125-010-1719-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  11 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)

Authors:  B Balkau; M A Charles
Journal:  Diabet Med       Date:  1999-05       Impact factor: 4.359

Review 3.  American College of Endocrinology position statement on the insulin resistance syndrome.

Authors:  Daniel Einhorn; Gerald M Reaven; Rhoda H Cobin; Earl Ford; Om P Ganda; Yehuda Handelsman; Richard Hellman; Paul S Jellinger; David Kendall; Ronald M Krauss; Naomi D Neufeld; Steven M Petak; Helena W Rodbard; John A Seibel; Donald A Smith; Peter W F Wilson
Journal:  Endocr Pract       Date:  2003 May-Jun       Impact factor: 3.443

4.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

5.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.

Authors:  S B Heymsfield; A S Greenberg; K Fujioka; R M Dixon; R Kushner; T Hunt; J A Lubina; J Patane; B Self; P Hunt; M McCamish
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

Review 6.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  Efficacy of leptin therapy in the different forms of human lipodystrophy.

Authors:  A Y Chong; B C Lupsa; E K Cochran; P Gorden
Journal:  Diabetologia       Date:  2009-09-02       Impact factor: 10.122

10.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Authors:  David B Savage; Garry D Tan; Carlo L Acerini; Susan A Jebb; Maura Agostini; Mark Gurnell; Rachel L Williams; A Margot Umpleby; E Louise Thomas; Jimmy D Bell; Adrian K Dixon; Fidelma Dunne; Romina Boiani; Saverio Cinti; Antonio Vidal-Puig; Fredrik Karpe; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  Diabetes       Date:  2003-04       Impact factor: 9.461
View more
  9 in total

1.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

Authors:  Jean L Chan; Karen Lutz; Elaine Cochran; Wenying Huang; Yvette Peters; Christian Weyer; Phillip Gorden
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

2.  The liver diseases of lipodystrophy: the long-term effect of leptin treatment.

Authors:  Elika Safar Zadeh; Andreea O Lungu; Elaine K Cochran; Rebecca J Brown; Marc G Ghany; Theo Heller; David E Kleiner; Phillip Gorden
Journal:  J Hepatol       Date:  2013-02-21       Impact factor: 25.083

Review 3.  Lipodystrophic diabetes mellitus: a lesson for other forms of diabetes?

Authors:  Romina Ficarella; Luigi Laviola; Francesco Giorgino
Journal:  Curr Diab Rep       Date:  2015-03       Impact factor: 4.810

Review 4.  Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Authors:  Cristina Adelia Meehan; Elaine Cochran; Andrea Kassai; Rebecca J Brown; Phillip Gorden
Journal:  Expert Rev Clin Pharmacol       Date:  2015-10-14       Impact factor: 5.045

5.  Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.

Authors:  Jalaja Joseph; Robert D Shamburek; Elaine K Cochran; Phillip Gorden; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2014-06-13       Impact factor: 5.958

6.  Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.

Authors:  Andreea O Lungu; Elika Safar Zadeh; Anne Goodling; Elaine Cochran; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

Review 7.  Syndromic insulin resistance: models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance.

Authors:  Phillip Gorden; Elika Safar Zadeh; Elaine Cochran; Rebecca J Brown
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

Review 8.  New advances in the treatment of generalized lipodystrophy: role of metreleptin.

Authors:  Alexander J Rodriguez; Claudio A Mastronardi; Gilberto J Paz-Filho
Journal:  Ther Clin Risk Manag       Date:  2015-09-16       Impact factor: 2.423

9.  Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD.

Authors:  Samir Softic; Jeremie Boucher; Marie H Solheim; Shiho Fujisaka; Max-Felix Haering; Erica P Homan; Jonathon Winnay; Antonio R Perez-Atayde; C Ronald Kahn
Journal:  Diabetes       Date:  2016-05-10       Impact factor: 9.461
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.